Picture of Aprea Therapeutics logo

APRE — Aprea Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Aprea Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

* Aprea Therapeutics Inc  APRE.OQ   APRE.O  is expected
to show no
change in quarterly revenue when it reports  results on November
7 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Aprea Therapeutics
Inc is
for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $3​, above​ its last closing price of $0.69.
​​​

This summary was machine generated November 4 at 14:33 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Aprea Therapeutics

See all news